Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) pyridin-2-yl) acetamide (b12) as a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor t inverse agonist

The nuclear receptor retinoic acid receptor-related orphan receptor gamma (ROR gamma, NR1F3, or RORc) exists in two isoforms, with one isoform (ROR gamma or RORc1) widely expressed in a variety of tissues, and the expression of the second isoform (ROR gamma t or RORc2) restricted to the thymus and cells of the immune system. ROR gamma t is a key regulator of the development and functions of T-helper 17 (Th17) cells. Clinical proof-of-concept (PoC) with small molecule inverse agonists of ROR gamma t has been achieved with VTP-43742 (Phase II) for the treatment of psoriasis, and pre-clinical PoC for this mechanism has also been established for the treatment of autoimmune diseases. A series of aryl sulfonyl derivatives as novel ROR gamma t inverse agonists were designed and synthesized based on VTP-43742. We conducted structural modifications that improved the activity profile. In pharmacodynamic (PD) studies, oral administration of compound b12 showed robust and dose-dependent inhibition of IL-6 and IL-17A cytokine expression. The ability of compound b12 to reduce the levels of IL-6 and IL-17A in vivo after oral dosing in mice, and a corresponding reduction in skin inflammation further supports the potential of small molecule ROR gamma t modulation as a therapeutic target for the treatment of inflammatory diseases.